

Osimertinib + chemo improves progression-free survival in advanced non-small cell lung cancer: Study

November 16 2023, by Elana Gotkine



For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer

progression-free survival (PFS) compared with osimertinib alone, according to a study published online Nov. 8 in the *New England Journal of Medicine*.

David Planchard, M.D., Ph.D., from Institut Gustave Roussy in Villejuif, France, and colleagues randomly assigned 557 [patients](#) with EGFR-mutated advanced NSCLC who had not previously received [treatment](#) for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed plus either cisplatin or carboplatin) or to receive osimertinib monotherapy (80 mg once daily) in a 1:1 ratio.

The researchers found that investigator-assessed PFS was significantly longer in the osimertinib-chemotherapy group versus the osimertinib group. Overall, 57 and 41 percent of patients in the osimertinib-chemotherapy group and osimertinib group, respectively, were alive and progression-free at 24 months.

Consistent with the primary analysis, PFS as assessed according to blinded independent review was significantly longer in the combination group. An objective (complete or partial) response was observed in 83 and 76 percent of patients in the osimertinib-chemotherapy and osimertinib groups; median response duration was 24.0 and 15.3 months, respectively. The combination group had a higher incidence of grade 3 or higher adverse events from any cause than the monotherapy group.

"Osimertinib plus [chemotherapy](#) with pemetrexed and a platinum-based agent significantly improved [progression-free survival](#) as compared with osimertinib alone in the context of first-line treatment of patients with EGFR-mutated advanced NSCLC," the authors write.

Several authors disclosed ties to AstraZeneca, which manufactures osimertinib and funded the study.

More information: David Planchard et al, Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC, *New England Journal of Medicine* (2023). [DOI: 10.1056/NEJMoa2306434](https://doi.org/10.1056/NEJMoa2306434)

Yi-Long Wu et al, Combination Therapy for EGFR-Mutated Lung Cancer, *New England Journal of Medicine* (2023). [DOI: 10.1056/NEJMe2311559](https://doi.org/10.1056/NEJMe2311559)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: Osimertinib + chemo improves progression-free survival in advanced non-small cell lung cancer: Study (2023, November 16) retrieved 12 May 2024 from <https://medicalxpress.com/news/2023-11-osimertinib-chemo-progression-free-survival-advanced.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
